About Compugen (NASDAQ:CGEN)
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Industry, Sector and Symbol
Industry Biotechnology & Medical Research
Trailing P/E Ratio-4.72222222222222
Forward P/E Ratio-4.15
Sales & Book Value
Price / Sales244.85
Price / CashN/A
Book Value$0.57 per share
Price / Book5.96
Return on Equity-87.08%
Return on Assets-72.10%
Compugen (NASDAQ:CGEN) Frequently Asked Questions
What is Compugen's stock symbol?
Compugen trades on the NASDAQ under the ticker symbol "CGEN."
How were Compugen's earnings last quarter?
Compugen Ltd. (NASDAQ:CGEN) posted its earnings results on Wednesday, February, 21st. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter. View Compugen's Earnings History.
When will Compugen make its next earnings announcement?
Where is Compugen's stock going? Where will Compugen's stock price be in 2018?
1 Wall Street analysts have issued twelve-month price objectives for Compugen's stock. Their predictions range from $14.00 to $14.00. On average, they anticipate Compugen's share price to reach $14.00 in the next twelve months. View Analyst Ratings for Compugen.
Who are some of Compugen's key competitors?
Some companies that are related to Compugen include GTX (GTXI), Protalix Biotherapeutics (PLX), Celldex Therapeutics (CLDX), Horizon Discovery Group (HZD), Chromadex (CDXC), Arbutus Biopharma (ABUS), NewLink Genetics (NLNK), Cellular Dynamics International (ICEL), CASI Pharmaceuticals (CASI), Sunesis Pharmaceuticals (SNSS), Arsanis (ASNS), Nabriva Therapeutics (NBRV), Corvus Pharmaceuticals (CRVS), Palatin Technologies (PTN), Bio-Path (BPTH), CTI BioPharma (CTIC), ArQule (ARQL) and Galectin Therapeutics (GALT).
Who are Compugen's key executives?
Compugen's management team includes the folowing people:
- Paul Jai Sekhri, Chairman of the Board (Age 59)
- Anat Cohen-Dayag Ph.D., President, Chief Executive Officer, Director (Age 48)
- Ari Krashin, Chief Financial Officer (Age 42)
- Zurit Levine Ph.D., Vice President - Research and Discovery (Age 47)
- John Hunter, Vice President - Antibody Research & Development (Age 52)
- Dov Hershberg, Director (Age 75)
- Michal Preminger Ph.D., Director
- Yair Aharonowitz Ph.D., Independent External Director (Age 74)
- Ruth Arnon, Independent Director (Age 84)
- Arie Ovadia, Independent External Director (Age 68)
Who owns Compugen stock?
Compugen's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Raging Capital Management LLC (7.18%), ARK Investment Management LLC (4.41%), Harel Insurance Investments & Financial Services Ltd. (1.86%), Rothschild Investment Corp IL (0.79%), Renaissance Technologies LLC (0.66%) and Taylor Frigon Capital Management LLC (0.55%). View Institutional Ownership Trends for Compugen.
Who sold Compugen stock? Who is selling Compugen stock?
Who bought Compugen stock? Who is buying Compugen stock?
Compugen's stock was purchased by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Harel Insurance Investments & Financial Services Ltd., Taylor Frigon Capital Management LLC, Anson Funds Management LP, Jane Street Group LLC, Renaissance Technologies LLC, Virtu Financial LLC and Paloma Partners Management Co. View Insider Buying and Selling for Compugen.
How do I buy Compugen stock?
Shares of Compugen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Compugen's stock price today?
One share of Compugen stock can currently be purchased for approximately $3.40.
How big of a company is Compugen?
Compugen has a market capitalization of $167.19 million and generates $710,000.00 in revenue each year. The biotechnology company earns $-31,500,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis. Compugen employs 98 workers across the globe.
How can I contact Compugen?
Compugen's mailing address is Azrieli Center, 26 Harokmim St. Bldg D, HOLON, 5885849, Israel. The biotechnology company can be reached via phone at +972-3-7658585 or via email at [email protected]
MarketBeat Community Rating for Compugen (CGEN)MarketBeat's community ratings are surveys of what our community members think about Compugen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Compugen (NASDAQ:CGEN) Earnings History and Estimates Chart
Compugen (NASDAQ CGEN) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/8/2018|| || || || || || || || |
|2/15/2017||Q416||($0.18)||($0.17)||$0.13 million||$0.05 million||View||Listen|
|11/7/2016||Q316||($0.14)||($0.15)||$0.41 million||$0.07 million||View||N/A|
|8/2/2016||Q116||($0.17)||($0.13)||$0.11 million||$0.50 million||View||N/A|
|5/10/2016||Q1||($0.16)||($0.17)||$0.12 million||$0.09 million||View||Listen|
|2/9/2016||Q415||($0.11)||($0.01)||$3.33 million||$8.30 million||View||N/A|
|11/3/2015||Q315||($0.15)||($0.13)||$0.92 million||$0.23 million||View||N/A|
|8/4/2015||Q215||($0.14)||($0.14)||$1.58 million||$0.22 million||View||N/A|
|5/5/2015||Q115||($0.13)||($0.12)||$1.88 million||$0.51 million||View||N/A|
|2/10/2015||Q414||($0.08)||($0.03)||$3.70 million||$6.60 million||View||N/A|
|10/29/2014||Q314||($0.11)||($0.11)||$1.90 million||$1.70 million||View||N/A|
|8/6/2014||Q214||($0.10)||($0.07)||$1.85 million||$2.00 million||View||N/A|
|5/19/2014||Q114||($0.11)||($0.04)||$0.16 million||$2.10 million||View||N/A|
|2/11/2014||Q413||($0.09)||$0.13 million||$1.80 million||View||N/A|
|10/29/2013||Q313||($0.12)||$0.11 million||$1.60 million||View||N/A|
|8/2/2013||Q2 2013||($0.09)||$0.02 million||View||N/A|
|4/25/2013||Q1 2013||($0.09)||$0.16 million||View||N/A|
Compugen (NASDAQ:CGEN) Earnings Estimates
2018 EPS Consensus Estimate: ($0.85)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Compugen (NASDAQ:CGEN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Compugen (NASDAQ CGEN)
No insider trades for this company have been tracked by MarketBeat.com
Compugen (NASDAQ CGEN) News Headlines
Compugen (NASDAQ:CGEN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Compugen (NASDAQ:CGEN) Income Statement, Balance Sheet and Cash Flow Statement
Compugen (NASDAQ CGEN) Stock Chart for Sunday, February, 25, 2018